Mechanisms of action of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF)

The Alfred Hospital0 个研究点目标入组 36 人开始时间: 2021年2月22日最近更新: 2021年3月1日

适应症

试验速览

暂无简介。

•LVEF less than or equal to 40%. NYHA II-IV.
•Ischaemic or non-Ischaemic aetiology.
•Stable heart failure therapy for 1 month (a <50% adjustment to diuretics is permissible between day -14 and day -28).
•Patients may be non-diabetic or T2DM (on stable therapy >12 weeks defined as < ±20% variability in the average daily dose or oral agents and/or < ±10% daily variability in insulin dose).

•Unstable heart failure or haemodynamics (eg SBP<90mmHg, poorly controlled AF – rate>90/min). Recent or active unstable coronary disease in the past 2 months or PCI with the past month or CABG within 3 months.
•Type 1 diabetes.
•Poorly controlled BSL (fasting plasma glucose level > 13.3 mmol/L).
•History of ketoacidosis or hyperosmolar state/coma within 6 months.
•Ongoing therapy with an SGLT2 inhibitor or GLP-1 receptor agonist.
•On monoamine oxidase inhibitors or tricyclic antidepressants.
•Body mass index (BMI) <20.0 kg/m2 or >40 kg/m2.
•eGFR <30 ml/min/1.73 m2.
•Other life limiting lesion (expected survival <2 years) including malignancy, advanced respiratory, GI, neurologic, haematologic disease. Active substance abuse including EtOH.
•Inability to provide written informed consent.

发起方

The Alfred Hospital